ARK Genomic Revolution ETF vs FedEx Corporation — how do they compare? ARK Genomic Revolution ETF trades at $44.61, while FedEx Corporation trades at $326.65 (market cap $76.28B). The key difference: FedEx Corporation pays a 1.51% dividend while ARK Genomic Revolution ETF pays none. Which is the better fit depends on your goals.
| ARKG | FDX | |
|---|---|---|
Sector | Sector/Thematic | Industrials |
52-Week High | $44.55 | $338.75 |
52-Week Low | $24.02 | $180.51 |
Market Cap | — | $76.28B |
Enterprise Value | — | $105.91B |
Dividend Yield | — | 1.51% |
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $44.69 with a 0.86% daily gain, showing bullish momentum with strong moving average signals but overbought oscillators. The ETF focuses on genomic revolution companies with 59% concentration in top 10 holdings and long-term EPS growth of 10.7%. Recent news highlights biotech sector strength and ARKG's recovery from July correction.
Outlook remains positive given biotech sector tailwinds including FDA friendliness and AI-driven drug discovery, though high RSI readings suggest near-term caution. Key risks include sector volatility and concentrated portfolio exposure.
FedEx (FDX) trades at $326.25, up 0.36% on the day, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $360.27. Recent earnings beats in Q4 2025 and Q1 2026 highlight strong profitability, with a net income margin of 4.68% and ROE of 14.82%. The company's Network 2.0 initiative aims for $2 billion in annual savings, driving efficiency gains amid a shift to premium logistics services.
The stock offers upside potential from cost-cutting and freight recovery, but faces risks from competitive pressures and economic sensitivity. Analysts are predominantly bullish (57% buy ratings), though elevated RSI levels suggest near-term overbought conditions. Long-term growth hinges on execution of margin improvements and volume normalization in the LTL market.
Trailing returns across standard periods
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →FedEx pioneered overnight delivery in 1973 and remains the world's largest express package provider. In its fiscal 2020 (ended May 2020), FedEx derived 51% of revenue from its express division, 33% from ground, and 10% from freight, its asset-based less-than-truckload shipping segment. The remainder comes from other services, including FedEx Office, which provides document production/shipping, and FedEx Logistics, which provides global forwarding. FedEx acquired Dutch parcel delivery firm TNT Express in 2016. TNT was previously the fourth-largest global parcel delivery provider.
Read more on FDX →